Background: Public health organisations use public health indicators to guide health policy. Joint analysis of multiple public health indicators can provide a more comprehensive understanding of what they are intended to evaluate. | 123 BEST ET al.
| INTRODUC TI ON
Public health indicators are commonly used to assess a population's health status. They are intended as an effective and uncomplicated way to compare public health between populations and over time. 1, 2 Public health organisations, including the World Health Organisation (WHO) and the European Commission, use public health indicators to evaluate interventions and guide policy. 3, 4 Congenital anomalies are an important public health concern given that they are major contributors to infant mortality, morbidity in childhood and lifelong disability. 5 The European Surveillance of Congenital Anomalies (EUROCAT) is a collaborative network of 43 population-based congenital anomaly registers, based in 23 countries. 6 The registries collect data on congenital anomalies occurring in live births, late miscarriages (20-24 weeks gestation), stillbirths (>24 weeks gestation), and termination of pregnancy for foetal anomaly (TOPFAs, any gestation). The registries each use multiple sources to ascertain cases and their outcomes, including hospital records (antenatal ultrasound, foetal medicine, cytogenetic laboratories, and paediatric surgery), birth and death certificates, and post-mortem examinations. 7 Registries vary in the age up to which they ascertain new diagnoses, but most registries are notified of cases diagnosed up to at least age 1 year. 7 EUROCAT surveys approximately 1.7 million births per year in Europe, representing 29% of the European birth population. 6 EUROCAT have developed six public health indicators that aim to evaluate the public health impact and assessment of interventions for congenital anomalies in Europe, using data routinely recorded by each registry. 8 Objective: To analyse variaitons in the prevalence of congenital anomaly-related perinatal mortality attributable to termination of pregnancy for foetal anomaly (TOPFA) and prenatal diagnosis of congenital anomaly prevalence.
Methods:
We included 55 363 cases of congenital anomalies notified to 18 EUROCAT registers in 10 countries during 2008-12. Incidence rate ratios (IRR) representing the risk of congenital anomaly-related perinatal mortality according to TOPFA and prenatal diagnosis prevalence were estimated using multilevel Poisson regression with country as a random effect. Between-country variation in congenital anomaly-related perinatal mortality was measured using random effects and compared between the null and adjusted models to estimate the percentage of variation in congenital anomaly-related perinatal mortality accounted for by TOPFA and prenatal diagnosis. 
Results

Conclusion:
We demonstrated an approach for analysing inter-linked public health indicators. In this example, as TOPFA and prenatal diagnosis of congenital anomaly prevalence decreased, the risk of congenital anomaly-related perinatal mortality increased. Much of the between-country variation in congenital anomaly-related perinatal mortality was accounted for by TOPFA, with a smaller proportion accounted for by prenatal diagnosis.
K E Y W O R D S
perinatal mortality, termination of pregnancy for foetal anomaly had higher prevalence of congenital anomaly-related perinatal mortality, although this was not formally tested. 8 Outside of the perinatal setting, previous studies have examined the association between several public health indicators relating to a range of conditions. 1, 9, 10 However, we are not aware of any studies, in the perinatal setting or otherwise, that have quantified the degree of variation in one indicator that may be attributable to another using variance explained measures in multilevel models. This approach may better explain relationships between inter-linked public health indicators, in all areas of research.
The aim of this study was to demonstrate a multilevel statistical method of analysing inter-linked public health indicators using an interesting example of EUROCAT public health indicators. Using our proposed method, we will show how to quantify what proportion of between-country variation in congenital anomaly-related perinatal mortality may be accounted for by TOPFA prevalence. We will also test the hypothesis that increased TOPFA prevalence is associated with decreased congenital anomaly-related perinatal mortality rates.
| ME THODS
| Data
Data on congenital anomalies notified to 18 full member EUROCAT registers in 10 countries between 1 January 2008 and 31 December 2012 were included in this study ( Table 1 ). In order to restrict our analysis to countries with high ascertainment of congenital anomalyrelated perinatal mortality, we used Boyle et als' approach of excluding countries where the EUROCAT infant mortality rate (in cases of congenital anomaly) was more than 20% lower than that reported by the WHO between 2005 and 2009. 11 EUROCAT defines a case of congenital anomaly as any case with at least one diagnosis in the Q chapter of the WHO International Classification of Disease (ICD) version 10, along with a limited set of conditions coded outside the Q chapter: D215, D821, D1810, P350, P352, and P371. Minor anomalies (eg, skin tags) are excluded if they occur in isolation; further details are available in the EUROCAT Guide 1.4. 12 There were 55 363 cases with congenital anomalies notified to the 18 participating registers, which covered 2 430 440 total births during the study period.
Indicators for the 18 registers were pooled according to country.
| Indicator definitions
The following indicators were used for each included country:
1. The prevalence of congenital anomaly-related perinatal mortality per 1000 total births: calculated as the number of cases with one or more congenital anomalies that resulted in foetal death ≥20 weeks gestational age or a death within the first week after birth, divided by the total number of live births and stillbirths in the country of interest, multiplied by 1000.
2. The prevalence of termination of pregnancy for foetal anomaly (TOPFA) per 1000 total births: calculated as the number of terminations of a pregnancy (at any gestation) following prenatal diagnosis of a congenital anomaly, divided by the total number of live births and stillbirths in the country of interest, multiplied by 1000.
3. The prevalence of prenatal diagnosis of a congenital anomaly per 1000 total births: defined as the number of prenatally diagnosed cases with a congenital anomaly divided by the total number of live births and stillbirths in the country of interest, multiplied by 1000.
| Statistical analysis
Prevalence rates for each indicator were calculated by country, with the corresponding 95% Poisson confidence intervals (CI). A null mul- 
What this study adds
Using multilevel analysis, we present a novel method for modelling the association between public health indicators that takes into account the hierarchical nature of data used to measure health indicators. Specifically, the method can be used to explore how, and the extent to which, different public health indicators may be related to one another.
In Model 1, the univariable association between (continuous) TOPFA prevalence and congenital anomaly-related perinatal mortality prevalence was modelled:
In model 2, the univariable association between (continuous) prenatal diagnosis of congenital anomaly prevalence and congenital anomaly-related perinatal mortality prevalence is modelled:
It is also possible to fit a multivariable model, in order to control for additional variables. To demonstrate, Model 3 was fitted with both our explanatory variables included:
We can now use the models to give us two different types of information. Firstly, γ 01 and γ 02 from the fixed effects part of the model can be interpreted as incidence rate ratios (IRRs), for example Secondly, the degree of variation in the outcome indicator that is "explained" by the explanatory indicator(s) can be calculated from the random effects part of the model. The variation between countries in the null model, which we refer to as the "baseline" variation, can be compared with the residual variation that remains after adjusting for explanatory indicators. This value can then be expressed as a percentage of the "baseline" variation between countries. So in our case, we can subtract the between-country variation after taking into account TOPFA and prenatal diagnosis of congenital anomaly prevalence ( * 00 ) from the baseline between-country variance (τ 00 ). The difference between the baseline and residual variance is then divided by the baseline variance in order to calculate a percentage of the total variance:
In this example, this statistic can be interpreted as the percentage of between-country variation in congenital anomaly-related perinatal mortality prevalence accounted for by TOPFA and prenatal diagnosis of congenital anomaly prevalence.
Analyses were performed in Stata 14 (using the mepoisson command).
| Missing data
Prenatal diagnosis data were not available for Antwerp at the time of analysis, and therefore, the prenatal diagnosis rate for Hainaut was used for Belgium. Prenatal diagnosis was not available for Dublin, and 0j = 00 + 01 TOPFA + 0j variance ( 0j ) = * 00 . 
| Ethics approval
Data were downloaded in aggregate form, and therefore ethical approval was not required for this study. However, each EUROCAT register has their own ethical approvals in place for the collection of data without consent. 
| RE SULTS
| Fixed effect associations
There was a univariable linear association between TOPFA prevalence and congenital anomaly-related perinatal mortality prevalence, with the risk of congenital anomaly-related perinatal mortality decreasing as TOPFA prevalence increased (Model 1, IRR 0.79, 95% CI 0.72, 0.86) ( Figure 1 ). There was also a univariable linear association between prenatal diagnosis of congenital anomaly and congenital anomaly-related perinatal mortality prevalence, with the risk of perinatal mortality decreasing with increasing prenatal diagnosis prevalence (Model 2, IRR 0.88, 95% CI 0.79, 0.97; Figure 2 ). In model 3, the association between congenital anomaly-related perinatal mortality prevalence and TOPFA prevalence strengthened after controlling for prenatal diagnosis prevalence (model 3, IRR 0.70, 95% CI 0.61, 0.81).
| Random effects
The prevalence of congenital anomaly-related perinatal mortality in the null model (Model 0) varied between countries with a "baseline" between-country variance (τ 00 ) of 0.28 (95% CI 0.11, 0.70). In the model including only TOPFA (Model 1), the between-country variation ( * 00 ) was 0.07 (95% CI 0.03, 0.18), meaning the prevalence of TOPFA accounted for 75.5% of the variation in congenital anomaly-related perinatal mortality between countries ( Table 2 ). In the model including only prenatal diagnosis only (Model 2), the between-country variation ( 00 ) was 0.17 (95% CI 0.07, 0.44), meaning the prevalence of prenatal diagnosis accounted for 37.7% of the between-country variation in perinatal mortality. In the model adjusted for TOPFA and prenatal diagnosis of congenital anomaly prevalence (Model 3), the between-country variation ( * 00 ) was 0.05 (95% CI 0.02, 0.13), meaning 83.0% of the variation in congenital anomalyrelated perinatal mortality was accounted for.
| COMMENT
| Principal findings
We have demonstrated a multilevel method for quantifying the degree of variation in one public health indicator that is attributable to another. Here, TOPFA prevalence was negatively associated with congenital anomaly-related perinatal mortality prevalence and accounted for a large percentage of between-country variation in perinatal mortality among babies with congenital anomalies. The 
| Strengths of the study
This study has several strengths. Firstly, the EUROCAT public health indicators we have presented are well defined, therefore satisfying an important criteria of an effective indicator. 13 EUROCAT uses these measures as quality indicators and due to the use of multiple sources of case ascertainment they are rigorously checked.
Congenital anomaly-related perinatal mortality is an important indicator that represents the burden of mortality and acts as a marker for quality of prenatal screening programmes, maternity care, and access/uptake of health services. Additionally, our results are arguably more robust because we excluded countries with potentially lower ascertainment of congenital anomaly-related perinatal mortality, including only countries with infant mortality rates comparable or higher than those reported by the WHO. 11 However, in applying this exclusion criteria, we cannot rule out the possibility that we excluded data from countries with genuinely low perinatal mortality rates.
Previous methods for analysing inter-linked public health indicators include presenting the indicators graphically or estimating only IRRs. 1, 14 Our proposed method allows the estimation of IRRs, but also provides a simple quantitative summary of the variation in one indicator that is attributable to one or more indicators. Although we have presented basic forms of the proposed technique, our approach is advantageous because it can be adapted to more complex scenarios. For example, we pooled the prevalence of the indicators by country in order to present the most simplistic form of the multilevel model. However, the prevalence also varied within country, for example prenatal diagnosis of congenital anomaly prevalence was 13.0 per 1000 in Basque Country but 6.9 per 1000 in Valencia Region of Spain. To account for this within country variation, we could have included an additional level within our multilevel model. 
| Limitations of the data
There are certain caveats and limitations in our study. While we can assess the relation between indicators and calculate the percentage of variation in one indicator that may be attributable to another, these represent empirical associations not causal ones. Contextual factors including those related to data issues and various possible connections between indicators should be considered in interpreting the statistical results from the proposed models. For example, we found a negative association between congenital anomalyrelated perinatal mortality prevalence and TOPFA prevalence; this association could be causal if severe cases of congenital anomaly are terminated more frequently and cannot contribute to perinatal mortality. Alternatively, increased termination rates may be acting as a proxy for improved access and/or uptake of health care or it could represent a more severe case mix of congenital anomalies, which would also influence perinatal mortality. The prevalence of TOPFA and congenital anomaly-related perinatal mortality may vary between countries due to differences in the coding of late TOPFA, given that some countries may code these as stillbirths as opposed to TOPFA. As always, any causal interpretations of the estimates need to be made in light of substantive knowledge of the field, including its inherent uncertainties.
| Interpretation
We found that increased prenatal diagnosis rates were associated with decreased risk of congenital anomaly-related perinatal mortality.
Countries with higher prenatal diagnosis of congenital anomaly prevalence had a higher prevalence of TOPFA, meaning the association may be mostly related to the impact of TOPFA. This is not surprising since prenatal diagnosis will not always result in a TOPFA but the vast Indicator (per 1000 births) studies that may be underpowered. [15] [16] [17] [18] Hospital-based studies have reported an increased risk of post-operative mortality in prenatally diagnosed cases of congenital heart disease, most likely because more severe phenotypes are diagnosed prenatally. 19, 20 However, in cardiovascular anomalies, the effect differs according to subtype. 21 Additionally A Canadian study also reported a negative association between TOPFA (occurring 20-23 weeks gestation) and infant deaths among cases of congenital anomaly after examining graphically their two indicators of interest. 22 In the European population, there may be other differences that contribute to variation in congenital anomaly-related perinatal mortality, for example differences in maternal age, parity, and multiple births are known to influence foetal and neonatal deaths, although with relatively small effect sizes. 23 Factors such as maternal smoking, alcohol use, obesity, socio-economic status, and diabetes are also known risk factors for perinatal mortality in general and vary by European country. [24] [25] [26] [27] [28] [29] [30] [31] Additionally, we combined all types of congenital anomaly. Countries with a higher prevalence of more severe congenital anomalies but with respectively lower prevalence of prenatal diagnosis or TOPFA are likely to have had even higher perinatal mortality than that described by the model.
| CON CLUS IONS
We have demonstrated a multilevel approach for quantifying the degree of variation in one public health indicator that may be attributable to another. In our example, we found a negative association between TOPFA rates and perinatal mortality among cases of congenital anomaly, which accounted for 75.5% of between-country variation. Prenatal diagnosis with TOPFA and prenatal diagnosis modelled together accounted for 83% of between-country variation in perinatal mortality.
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